Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026

DATE OF BOARD MEETING

VOLUNTARY ANNOUNCEMENT - Receipt of US$650 Million Upfront Payment from AbbVie under the Exclusive License Agreement for RC148

VOLUNTARY ANNOUNCEMENT - Approval of the New Drug Application for Disitamab Vedotin for the Indication of HER2-Expressing Urothelial Carcinoma

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026

Voluntary Announcement - NMPA APPROVES THE CLINICAL TRIAL OF BISPECIFIC ANTIBODY-DRUG CONJUGATE (BISPECIFIC ADC) RC288 FOR INJECTION

VOLUNTARY ANNOUNCEMENT - Approval of the New Drug Application for Disitamab Vedotin for the Indication of HER2-Low Breast Cancer with Liver Metastases

DATE OF BOARD MEETING

Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026

INSIDE INFORMATION - 2025 ANNUAL RESULTS UPDATE ANNOUNCEMENT